In addition to infertility treatment mandates, SB2572 also requires that health insurance policies for individuals aged 45 and older provide coverage for annual menopause health visits. Furthermore, the bill stipulates that coverage must be extended for all types of injectable medications (both on-label and off-label) aimed at improving glucose levels or weight loss for adults with conditions such as prediabetes, gestational diabetes, or obesity. These changes are intended to enhance the comprehensiveness of health care plans in Illinois, reflecting a broader commitment to women’s health and chronic disease management.
Summary
SB2572, introduced by Senator Cristina Castro, is a legislative proposal that amends the Illinois Insurance Code concerning health insurance policies, particularly targeting infertility coverage. The bill mandates that any group policy offering pregnancy-related benefits for more than 25 employees must include specific coverage for diagnosing and treating infertility starting January 1, 2024. This includes coverage for various medically accepted procedures such as in vitro fertilization, gamete intrafallopian tube transfer, and more, which are subject to certain clinical guidelines and requirements including screening before embryo implantation.
Contention
There are concerns regarding how these additional mandates might impact the cost of health insurance premiums. While proponents argue that comprehensive coverage will ultimately lead to better health outcomes and reduced long-term costs by facilitating earlier and more effective treatment, skeptics worry about the financial burden that these requirements could impose on employers and insurance providers. The debate encapsulates the ongoing dialogue about health care affordability versus the necessity of robust patient care and the right to comprehensive health services.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.
Requires health insurance plans to provide coverage for continuous blood glucose monitors for all children; requires coverage for glucose monitoring devices for all sugar disorders.
To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.